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Abstract 
Background: Physical performance phenotypes are formed by the 
interaction of genetic and environmental factors, and gene 
polymorphisms can influence physical and athletic abilities. An ACE 
gene insertion/deletion (I/D) polymorphism has been reported to 
influence physical performance, but its mechanism remains 
controversial. 
Methods: The frequency of this polymorphism in 146 healthy Iranian 
males was determined. Then, the associations between different ACE 
genotypes with physical performance factors were investigated for 43 
of the 146 participants. 
Results: The frequencies of DD, ID and II genotypes were 38.5%, 
41.5%, and 20%, respectively. Although there were no significant 
associations between the ACE polymorphisms and physical 
performance factors, the pulse pressure amplification, post-exercise 
heart rate, and resting heart rate were significantly different between 
variants with and without the I allele (P=0.02, 0.04, and 0.05, 
respectively). Furthermore, the ACE polymorphism was a significant 
predictor of exercise endurance and ventricular function in 
multivariate analyses (P<0.05). 
Conclusions: The ACE polymorphism correlated with cardiovascular 
determinants of physical performance, rather than musculoskeletal 
factors. Therefore, the ACE I/D polymorphism could not be utilized as 
a singular genetic biomarker for the assessment of physical 
performance in the Iranian population. However, a combination of 
genetic and cardiovascular biomarkers may determine physical 
performance capacities. 
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Introduction 
Over 20,000 genes contain a myriad of variations that 
define human phenotypes. Physical and athletic performance is 
the result of a vast array of phenotypes such as muscle strength, 
skeletal structure, tendon elasticity, and heart and lung size. 
Each phenotype is the outcome of complex interactions 
between different body systems.1 Previous studies have shown 
there are many genetic factors that influence physical 
performance through different human populations. These genes 
are involved in endurance abilities, muscle performance, 
tendon apparatus, ligamentous apparatus, and psychological 
aptitudes.2 Many polymorphic genes have been reported as 
genetic markers associated with athletic and physical 
performance, including angiotensin-converting enzyme (ACE), 
bradykinin receptor (BDKRB2), α-actinin-3 (ACTN3), creatine 
kinase (CKM), alpha-2A adrenoceptor (ADRA2A), sodium 
potassium adenosine triphosphate (Na+-K+-ATPase), 
peroxisome proliferator-activated receptor alpha (PPARα), 
peroxisome proliferator-activated receptor-γ coactivator 1α 
(PPARGC1A), endotelial PAS domain protein 1 (EPAS1), 
leukocyte antigens, and mitochondrial DNA (mtDNA) have 
been mentioned most frequently in the literature.3 
The ACE gene has been reported to be an influential factor 
on human physical performance.4 This gene encodes the ACE 
enzyme, which plays an important role in the renin-angiotensin 
system (RAS) pathway, which controls the homeostasis of the 
human circulatory system. ACE converts angiotensin I to 
angiotensin II, which acts as a potent vasoconstrictor. ACE 
hydrolyzes bradykinin, a vasodilator, so it reduces peripheral 
resistance, which consequently leads to lower blood pressure.5 
There is a common genetic variation in intron 16 of the ACE 
gene that consists in the absence (allele D) or presence (allele I) 
of a 287 bp Alu sequence. This insertion/deletion (I/D) 
polymorphism (rs1799752) accounts for about half of the 
variations in serum ACE levels. Allele D is associated with 
increased levels of ACE in the circulatory system and other 
tissues.6,7 Previous studies have shown that, allele I of ACE is 
associated with endurance-oriented performance, while allele D 
is related to strength-oriented performance.8 
The ACE I/D polymorphism has been reported to have an 
association with physical performance in other populations in 
the world. Because physical performance could be influenced 
by individuals' genetic background in different populations, in 
this study we aimed to determine whether there were any 
associations between different ACE genotypes, physical 
performance, and cardiorespiratory fitness in the Iranian 
population. 
Materials and Methods  
The participants for this study were randomly recruited 
from a healthy Iranian male population, ages 20–24 years old, 
in a military headquarters. In total, there were 146 individuals 
included in the genotyping phase of the study. Also, 45 of these 
individuals voluntarily participated in a series of physical 
performance, cardiorespiratory and cardiovascular evaluation 
tests. Any history of symptomatic cardiovascular diseases or 
diabetes mellitus was grounds for exclusion, but no cases of 
these conditions were detected. Two individuals could not 
complete their tests due to an episode of ankle sprain that 
limited their preparedness for the tests. Therefore, the physical 
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performance data for 43 participants were analyzed. This study 
was approved by the Research Ethics Committee of Aja 
University of Medical Sciences. The participants signed an 
informed consent form prior to taking part in the study. 
About 5 ml of peripheral blood was for each person and 
transferred to a laboratory in EDTA-containing tubes for DNA 
extraction. The whole genomic DNA was extracted using the 
High Pure PCR Template Preparation Kit (Roche, Mannheim, 
Germany) according to the manufacturer’s protocol. The 
primer pair: F: 5΄-CTGGAGACCACTCCCATCCTTTCT-3΄ 
and R: 5΄-GATGTGGCCATCACATTCGTCAGAT-3΄ was 
used to amplify and genotype the participants, using PCR and 
agarose gel electrophoresis. PCR was performed at 95˚ pre-
denaturation for 4 min, followed by 33 cycles of denaturation 
at 94˚ for 45 s, annealing at 60˚ for 30 s, extension at 72˚ for 40 
s, and one final extension cycle of 72˚ for 5 min. 
The participants exercised on a treadmill according to the 
Bruce protocol; the VO2 max values were estimated by 
algorithms incorporated into the stress test software. 
Anthropometric measures were calculated using body 
composition analyzer (Inbody 220, South Korea). Flexibility 
was examined by the Wells Sit and Reach test. Two-minute 
push-up and sit-up tests were used to determine muscle 
endurance. The maximal and average strength of hand 
mascules were measured by mechanical dynamometer. Arterial 
evaluation was performed by SphygmoCor (Atcore Medical, 
Sydney, Australia), and included assessments of the augmentation 
index, central blood pressure, aortic pulse pressure, reflection 
time of the propagated pulse as well as ejection duration, and 
subendocardial viability index. Resting heart rate was 
determined by the participants measuring their rate, following 
instruction by the researchers, for three mornings before getting 
up from bed. Blood pressure was measured before and after the 
exercise protocol using an automated brachial oscillometric 
device (M10-IT; Omron, Kyoto, Japan). Pulse pressure 
amplification was defined as the increment in pulse pressure 
from the aortic to radial regions. Circulatory power was 
calculated as the product of oxygen and maximal systolic 
Blood Pressure (SBP) during exercise, and the rate-pressure 
product was calculated as the maximal HR multiplied by 
maximal SBP per 100 means divided by 100. HR reserve 
(HRR) was calculated using the formula below: HRR = [(peak 
HR –HR at rest) / (220–age–HR at rest)] × 100 
The genotype and allele frequencies were determined by 
gene counting. The data analysis was performed using IBM-
SPSS Version 24 for comparisons between the genotypes and 
determinant factors for physical performance. The Mann–
Whitney U-test and ANOVA statistical analyses were carried 
out to compare the physical performance as well as the 
hemodynamic indices in different ACE genotype groups. 
Multivariate analysis modeled the determinant factors for 
ventricular function, arterial function, and physical 
performance. The significant level was set at 0.05. 
Results 
In order to find out the frequency of ACE I/D genotypes, 
PCR and gel electrophoresis techniques were performed in our 
146 samples (table 1). The frequencies of DD, ID and II 
genotypes were 38.5%, 41.5%, and 20%, respectively (figure 1). 
The PCR products for different genotypes are shown in figure 1.  
Figure 1. ACE I/D gene polymorphism genotyping. The investigation of ACE 
genotype frequencies in the population showed higher percentages for ID 
genotypes. Different genotypes of ACE I/D polymorphism are shown on 1.5% 
agarose gel. Genotype II (wells 1 and 2), genotype ID (wells 3 and 4), and 
genotype DD (wells 5 and 6), along with 100bp DNA ladder (L) 
Of the 43 people who participated in physical performance 
tests, there were 26 people with allele I (ID and II) and 17 
people without allele I (DD). The statistical data analysis using 
the Mann–Whitney U-test showed no associations between 
ACE polymorphisms and physical performance indices. 
Nevertheless, it showed an association between cardiovascular 
factors such as pulse pressure (PP) amplification (P=0.02), 
heart rate increase during exercise (P=0.037), and heart rate at 
rest (P=0.05) with the ACE polymorphism (Table 2). In 
addition, the association between PP amplification and the 
polymorphism was significant even after controlling for age 
(P=0.004). In multivariate analysis for exercise endurance, the 
ACE polymorphism effect was unmasked (β=0.34, P=0.047) 
after controlling for age, arterial stiffness, diastolic function, 
heart rate, and body fat (R2=53.8%). More importantly, the 
ACE polymorphism was a significant determinant of 
ventricular performance as expressed by PP amplification 
(P=0.004) after adjusting for age. Similarly, rate pressure 
product was predicted by the ACE polymorphism (P=0.049) 
and arterial stiffness (P=0.015) even after adjustment for age 
(table 3).  
Table 1. Genotypes and allele frequencies of ACE I/D gene in the total study 
sample (N=146) 
 Genotype frequencies (%)  Allele frequencies (%) 
 DD ID II  D I 
N=146  56 (38.5) 61 (41.5) 29 (20)  173 (59.3) 119 (40.7) 
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Table 3. Multivariate analysis for the rate-pressure product 
Source Type III Sum of Squares df Mean Square F P.V 
Corrected Model 22411.27(a) 7 3201.61 2.88 0.02 
Intercept 124846.00 1 124846.00 112.38 0.00 
Age 2759.20 1 2759.20 2.48 0.13 
ACE polymorphism 4679.31 1 4679.31 4.21 0.05 
Level of adjusted augmentation index  13821.24 3 4607.08 4.15 0.01 
Interaction 2736.78 2 1368.39 1.23 0.31 
Error 32215.63 29 1110.88   
Total 4610291.42 37    
Corrected Total 54626.90 36    
 
Discussion 
Physical performance, like other human phenotypes, results 
from an interaction between genetic factors and environmental 
stimuli. These athletic phenotypes, like endurance capacity, 
muscle performance, and psychological aptitudes have been 
mentioned to have genetic influences.2,9 There is a complicated 
relationship between physical performance with a physical 
activity, environmental factors, and genetic factors, and these 
associations differ between individuals and populations. 
Therefore, finding and selecting biological markers to achieve 
a reliable measure for the evaluation of physical performance 
can be challenging. Many studies support a significant 
association for increased endurance-based physical 
performance with the ACE II genotype compared to D-allele 
carriers (DD+ID).8,10-12 On the other hand, there are also some 
other studies that contradict these findings and suggest an 
association of D allele/DD genotype with endurance athletes' 
phenotypes.13-15 However, there have been some studies that 
suggest no association between the ACE I/D polymorphism 
and physical performance.16,17 In a meta-analysis by Ma et al., 
the association of sport performance with ACE I/D 
polymorphisms in 25 previous studies were summarized.18 
While the meta-analysis showed no statistically significant 
association between the ACE I allele and endurance-based 
activities, it suggests a significant association between the ACE 
II genotype and endurance-oriented athletic activities. These 
results demonstrate complicated mechanisms of physical 
performance containing genetic bases; many genes may 
influence the development of physical fitness. For instance, it 
has been noted that the influence of the ACE I/D gene 
polymorphism might be due to variations in nearby loci such as 
growth hormone (GH) gene that are linked to the ACE 
genotype.1 
In our study, we did not find any association between the 
ACE gene I/D polymorphism and physical performance in 
univariate analysis, which might be due to the homogeneity of 
the sample; however, we found an association between the 
ACE polymorphism and cardiovascular markers. In addition, 
multivariate models of analysis showed this polymorphism had 
an important role in the maximum tolerated distance of running 
among participants. In the DD group, the vascular function and 
cardiac performance were more effective, and it seems DD 
genotypes had a better response to exercise. In other words, it 
appears that in such a normal and healthy population, the DD 
genotype holders have more renin-angiotensin activity, which 
in turn causes a better hemodynamic response in the 
cardiovascular system. The increase in the renin-angiotensin 
system in abnormal ranges or in an individual lacking 
cardiovascular compensation could lead to an increased cardiac 
load, and finally cardiac hypertrophy, ventricular stiffness, and 
diastolic dysfunction. This process could finally lead to 
reduced physical performance. Therefore, the impact of the 
ACE polymorphism is not as simple as it was previously 
presumed. It may depend on the level of cardiac reserve and 
Table 2. The measures between physical performance and cardiovascular factors with two ACE genotype groups (DI/II and DD) 
P.V DD variant DI and II variants (%)  
0.67 0.76 (0.11) 0.74 (0.41) Tolerated distance 
0.99 9.5 (1.0) 9.5 (1.3) Tolerated time 
0.84 35.7 (6.7) 35.2 (7.3) VO2 Max 
0.78 12.6 (1.3) 12.6 (1.2) Max MET 
0.53 44.0 (6.5) 45.9 (8.3) Sit and Reach 
0.89 79.6 (14.9) 81.1 (13.7) Maximal force 
0.60 52.2 (14.9) 54.6 (10.3) Average force 
0.05 90.4 (12.6) 80.9 (13.4) Resting HR 
0.07 132.6 (10.7) 126.4 (11.3) Resting radial SBP 
0.84 78.8 (15.6) 81.6 (10.6) Resting DBP 
0.37 40.3 (8.7) 38.9 (8.9) Radial pulse pressure 
0.99 99.4 (10.7) 98.7 (10.5) Aortic SBP 
0.81 75.9 (9.3) 75.1 (8.5) Aortic DBP 
0.74 23.5 (5.2) 23.6 (5.0) Aortic pulse pressure 
0.02 172.7 (10.4)* 164.0 (11.2) PP amplification 
0.39 60.5 (15.8) 55.1 (15.7) SBP 
0.03 90.9 (11.2)* 99.8 (16.6) HR 
0.77 7034.9 (1538.5) 6741.3 (1695.1) Circulatory power 
0.63 357.9 (23.7) 347.1 (45.1) Rate-pressure product 
0.48 1.0 (0.05) 0.99 (0.1) Heart rate reserve 
0.98 4.7 (7.9) 4.9 (8.0) Adjusted augmentation index 
0.12 149.2 (6.8) 155.0 (12.5) Pulse wave reflection time 
*pulse pressure (PP) amplification  
*HR: heart rate 
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compensation. As a result, the DD genotype leads to an 
increased risk of high altitude syndrome in climbers and 
ischemic heart disease in elderly. All of these could be 
explained by the role of ACE.  
The distributions of three ACE genotypes in our study were 
38.5%, 41.5% and 20% for DD, ID, and II, respectively. Our 
findings are in agreement with previous studies from Iran, in 
which the I and D allele frequencies were similar.19-21 Our 
estimated ACE different genotype frequencies are significantly 
diﬀerent from those reported for Korean and Japanese 
populations, which, in comparison to our results, show higher 
D allele frequencies and lower I allele frequencies. 
Furthermore, the I/D allelic frequencies are different from 
those reported in European countries, and the I allele frequency 
is lower in our population. However, our frequencies were 
similar to the rates recorded in the Greek population.22 
The limited sample size for the second phase of the study 
could be a major limitation and a source of type 2 error. Further 
investigation with larger sample sizes could be useful, 
particularly in terms of ascertaining cardiovascular variables 
that showed non-significant trends between the groups. Our 
findings on the frequencies of ACE I/D polymorphisms could 
be generalized to the healthy Iranian male population. The 
results of the second phase of this study could be generalized to 
the similar groups; however, the purpose to explore the 
pathophysiological relations between the elements. ACE 
polymorphisms are more likely to correlate with cardiovascular 
determinants of physical performance rather than 
musculoskeletal factors. The net impact of ACE polymorphism 
is likely to be on the cardiovascular system rather than 
musculoskeletal condition. Therefore, by ACE activation 
young males (with good cardiovascular reserve) would take 
benefits whereas it may followed by adverse performance when 
a decompensated cardiovascular state is present. 
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